Combination treatment for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have esophageal cancer that has spread or cannot be removed with surgery, and it has grown after your first treatment.
- You have not had a stent placed in your esophagus or windpipe.
- You have not been treated with a TROP2-targeted drug or a topoisomerase I inhibitor (such as irinotecan).
- You have not had serious side effects from previous immunotherapy that haven't resolved.
- You do not have active autoimmune disease, interstitial lung disease, or other serious lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs (sacituzumab tirumotecan and another drug) for people with advanced esophageal cancer. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests two drugs, sacituzumab tirumotecan and toripalimab, given before surgery for esophageal cancer that has spread nearby but is still removable. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests a combination of three drugs—becotatug vedotin, tislelizumab, and low-dose lenvatinib—for people with advanced esophageal cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.